Government’s drug price caps may trigger showdown with US

img{border:0;clear:both;display:block;float:none;height:auto !important;margin: 3px 10px 3px 0;max-width:100% !important}
object, embed{border:0;clear:both;display:block;float:none}
a img{text-decoration:none}
.content * {font-family:’AvenirNext-Regular’, Avenir, ‘Helvetica Neue’, Arial, Helvetica, sans-serif;font-size:18px;line-height:1.4;color:#333 !important;}
font {line-height: inherit !important; font-size: inherit !important}
a, a:visited, .content a {color:#09f !important;text-decoration:none !important}
h1 a {color: white !important}

h1 {font-size:36px !important}
h2 {font-size:27px !important}
h3 {font-size:21px !important}
h4 {font-size:18px !important}
h5 {font-size:18px !important}
h6 {font-size:18px !important}
h1, h2, h3 { line-height: 1.125 !important }
h4, h5, h6 { line-height: 1.25 !important }

@media screen and (max-width:700px) {
.content {
width: 100%!important;

US pharma biggies are at the receiving end of the Donald Trump administration’s ire due to rising drug prices in that country, and this may cause anxiety for the Indian government as well as domestic generic companies.

via Industry-The Economic Times

RSS Feed

RSS feed to email